Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.
StockStory.org on MSN41m
Envista’s (NYSE:NVST) Q4 Sales Beat EstimatesDental products company Envista Holdings (NYSE:NVST) announced in Q4 CY2024, with sales up 1.1% year on year to $652.9 ...
Hosted on MSN33m
Ford (NYSE:F) Delivers Strong Q4 Numbers But Stock DropsAutomotive manufacturer Ford (NYSE:F) reported Q4 CY2024 results , with sales up 4.9% year on year to $48.2 billion. Its non-GAAP profit of $0.39 per share was 20.4% above analysts’ consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback